BMRN in the 13F filings
Biomarin Pharmaceutical Inc · CUSIP 09061G101
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 5 Feb 2026
- Managers listing it
- 41
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 15 listed it in both
- Shares listed
- 48,225,364
- combined, among listed positions
- Reported value
- $2.9bn
- combined, at the quarter end
Among the 92 comparable managers: 24 buyers (opened or added shares) and 19 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,516,856.
Managers listing BMRN in Q4 2025
41 of 41 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 1,837,071 shares now+1,444,256
- Citadel Advisors LLCexisting position · 1,364,691 shares now+966,844
- Wellington Management Group LLPnew position · 785,095 shares now+785,095
- AQR Capital Management LLCexisting position · 6,686,916 shares now+754,807
- D. E. Shaw & Co.existing position · 1,004,029 shares now+728,791
Reductions
- Viking Global Investors LPexisting position · 6,036,936 shares now-2,285,243
- Man Group PLCexisting position · 361,495 shares now-1,131,884
- Renaissance Technologies LLCexisting position · 1,324,971 shares now-568,600
- Schonfeld Strategic Advisors LLCexisting position · 257,419 shares now-217,979
- Voloridge Investment Management LLCexisting position · 444,890 shares now-156,156
New positions and exits
New (8)
Exited (3)
- Balyasny Asset Management LLCwas $14m
- PDT Partners LLCwas $2.9m
- Quantbot Technologies LPwas $492k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $2.3bn | n.a. | n.a. |
| Q3 2013 | 14 | $2.8bn | n.a. | n.a. |
| Q4 2013 | 11 | $2.5bn | n.a. | n.a. |
| Q1 2014 | 8 | $2.1bn | n.a. | n.a. |
| Q2 2014 | 9 | $1.9bn | n.a. | n.a. |
| Q3 2014 | 8 | $2.5bn | n.a. | n.a. |
| Q4 2014 | 12 | $3.3bn | n.a. | n.a. |
| Q1 2015 | 15 | $5.4bn | n.a. | n.a. |
| Q2 2015 | 14 | $6.3bn | n.a. | n.a. |
| Q3 2015 | 20 | $5.1bn | n.a. | n.a. |
| Q4 2015 | 14 | $4.8bn | n.a. | n.a. |
| Q1 2016 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2016 | 11 | $2.7bn | n.a. | n.a. |
| Q3 2016 | 17 | $3.7bn | n.a. | n.a. |
| Q4 2016 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2017 | 11 | $3.2bn | n.a. | n.a. |
| Q2 2017 | 14 | $3.2bn | n.a. | n.a. |
| Q3 2017 | 16 | $3.9bn | n.a. | n.a. |
| Q4 2017 | 16 | $3.8bn | n.a. | n.a. |
| Q1 2018 | 17 | $3.3bn | n.a. | n.a. |
| Q2 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q3 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2019 | 15 | $3.1bn | n.a. | n.a. |
| Q2 2019 | 19 | $3.0bn | n.a. | n.a. |
| Q3 2019 | 13 | $2.1bn | n.a. | n.a. |
| Q4 2019 | 15 | $3.0bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.5bn | n.a. | n.a. |
| Q2 2020 | 11 | $3.6bn | n.a. | n.a. |
| Q3 2020 | 12 | $3.0bn | n.a. | n.a. |
| Q4 2020 | 12 | $3.7bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.1bn | n.a. | n.a. |
| Q2 2021 | 11 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 14 | $3.0bn | n.a. | n.a. |
| Q4 2021 | 14 | $3.4bn | n.a. | n.a. |
| Q1 2022 | 19 | $3.0bn | n.a. | n.a. |
| Q2 2022 | 21 | $2.9bn | n.a. | n.a. |
| Q3 2022 | 25 | $3.1bn | n.a. | n.a. |
| Q4 2022 | 26 | $4.0bn | n.a. | n.a. |
| Q1 2023 | 20 | $3.3bn | n.a. | n.a. |
| Q2 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q3 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q4 2023 | 22 | $4.1bn | 14 | 8 |
| Q1 2024 | 19 | $3.6bn | 16 | 4 |
| Q2 2024 | 16 | $3.3bn | 10 | 6 |
| Q3 2024 | 16 | $3.0bn | 9 | 8 |
| Q4 2024 | 14 | $3.0bn | 11 | 2 |
| Q1 2025 | 16 | $3.3bn | 12 | 3 |
| Q2 2025 | 16 | $2.5bn | 12 | 5 |
| Q3 2025 | 16 | $2.3bn | 10 | 5 |
| Q4 2025 | 21 | $2.4bn | 24 | 19 |
| Q1 2026 | 15 | $2.6bn | 14 | 26 |
| Q2 2026 | 12 | $2.2bn | 13 | 22 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BMRN and LLY →BMRN and JNJ →BMRN and VRTX →Choose a stock to compare with BMRN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BMRN, latest filings →Back to the 13F Explorer →